

Approaches to Neoadjuvant Treatment in Melanoma

A public workshop organized by the FDA and MRA

November 13, 2019 By [Melanoma Research Alliance](#)

On November 6, 2019, the FDA and the Melanoma Research Alliance co-hosted a public workshop to identify, discuss, and address key issues, challenges and opportunities in the pursuit of neoadjuvant therapies for patients with surgically resectable melanoma. This exciting, half-day workshop brought together clinicians, researchers, regulators, and patient advocates to explore opportunities and discuss challenges in the development of neoadjuvant therapies for melanoma. The workshop took place at National Harbor (outside of Washington, D.C.) with opportunities to participate in person and via simultaneous webcast.

Keynote Lecture: A role and rationale for neoadjuvant therapy in the melanoma treatment landscape & Session 1: Foundational Experience from Other Areas in Oncology

[Presentation 1: Suzanne Topalian, MD](#)

[Presentation 2: Angela DeMichele, MD, MSCE](#)

[Presentation 3: Patricke Forde, MB MRCP UK](#)

[Presentation 4: Laleh Amiri-Kordestani, MD](#)

[Presentation 5: Donald Berry, PhD](#)

Session 2: Current Melanoma Neoadjuvant Experience

[Presentation 6: Caroline Robert, MD, PhD](#)

[Presentation 7: Jennifer Wargo, MD, MMSc](#)

[Presentation 8: Janis Taube, MD](#)

Session 3: Optimal Clinical Trial Design and Patient Selection

[Presentation 9: Charlotte Ariyan, MD, PhD](#)

[Presentation 10: Michael Atkins, MD](#)

[Presentation 11: Christian Blank, MD, PhD](#)

[Presentation 12: Rajeshwari Sridhara, PhD](#)

Panel Discussion with Audience Q&A — Working Together to Develop Neoadjuvant Therapies in Melanoma

This post was originally published by the [Melanoma Research Alliance](#). It is republished with permission.

© 2026 Smart + Strong All Rights Reserved.

<http://beta.docker.cancerhealth.com/blog/approaches-neoadjuvant-treatment-melanoma>